Our clinical trial examines the effects of individualized treatment on patients with metastatic breast cancer (stage IV). Individualized treatment, known as targeted therapy, provides doctors a better way to treat stage IV breast cancer, based not on the type of cancer, but on its molecular architecture. This gets us better therapy prediction and better results and closer to removing the word ‘terminal’ from our cancer vernacular.
In 2015, Side-Out was honored to be awarded the PhRMA Community Champion Research & Hope Award.
Since 2010, the Side-Out Foundation has been dedicated to funding breast cancer education and cutting-edge breast cancer research/treatment in order to extend the lives of those living with stage IV. Our journey has produced a series of volleyball sponsored clinical trials, funded and managed by Side-Out and its team of leading breast cancer oncologists and molecular biologists. Side-Out’s clinical trials go above and beyond “Standard of Care”, proving multi-omic molecular profiling (including genomic, proteomic, and phosphoproteomic analysis) is beneficial in selecting treatment for late-stage breast cancer.
Side-Out also supported the proteomic and phosphoproteomic work of the I-SPY 2 trial, another ground-breaking neoadjuvant clinical trial targeting patients with stage II/III disease.
The major benefit was the development of a body of proteomics data for early and late stage disease which provided a significant contribution to the accelerated approval of new effective drugs and actionable information for other forms of cancer.
Dedication and focus also produced and enabled the establishment of the “Side-Out Foundation Bio-Medical Informatics Database” on Metastatic Breast Cancer, located at George Mason University, College of Science, for all to benefit from.
The major benefits of these Side-Out Foundation efforts were many fold:
1. Published and presented clinical evidence that revealed that patients with metastatic breast cancer who went through Side-Out’s multi-omic profiling and treatment selection achieved significant improvement in survival. Based on these results, The Side-Out Foundation is expanding its clinical trial efforts to rigorously evaluate these findings in larger populations of women including those with bone metastasis.
2. The first-ever development of a body of multi-omics molecular database of metastatic breast cancer. This unique database contains genomic, proteomic, and phosphoproteomic data along with clinical-epidemiological data, treatment type and outcomes. This database is being made publicly available as an inaugural effort to spur more research and discovery by the entire scientific community and will be expanded by each new Side-Out Foundation sponsored trial.
3. Identification of new classes of protein and phosphoprotein markers that predict therapy response to a number of experimental targeted inhibitors in the I-SPY 2 TRIAL for women with Stage II/III breast cancer.
The Side-Out Protocol brings together the diverse skills and unique experiences of community oncologists, nurses and researchers in the field of molecular medicine. The Side-Out Foundation’s trial is managed by Translational Genomics Research Institute (TGen) Drug Development Services (TD2).
Join our fight in the match against stage IV breast cancer.
Get To Know Us
© Side-Out Foundation, a 501(c)(3) non-profit
Dig Pink® is a registered trademark of the Side-Out Foundation
